A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment

Part of paid clinical trials in Chandler, Arizona.

Sponsor
Incyte Corporation
Study ID
NCT07559474
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Hepatic Insufficiency
  • Liver Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • INCB123667 — DRUG
    single dose administered orally

Study Details

This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with moderate or severe hepatic impairment.

Key Dates

First listed
Apr 30, 2026
Start date
May 27, 2026
Status verified
Jun 2026
Primary completion
Apr 13, 2027
Completion
Apr 13, 2027

Study Design

Enrollment
16 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1: Moderate hepatic function
    Participants with moderate hepatic impairment will be enrolled in Cohort 1.
  • Experimental: Cohort 2: Severe hepatic function
    Participants with severe hepatic impairment will be enrolled in Cohort 2.

Primary Outcome Measure

PK for plasma INCB123667: Cmax [ Time Frame: Up to approximately 2 months ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Arizona Clinical Trials - the Institute For Liver HealthChandlerArizona85225-
Orlando Clinical Research CenterOrlandoFlorida32809-
Pinnacle Clinical ResearchSan AntonioTexas78229-
Texas Liver Institute - American Research CorporationSan AntonioTexas78215-

Find similar trials in Chandler, AZ

By research site
Arizona Clinical Trials - the Institute For Liver Health· Chandler, AZOrlando Clinical Research Center· Orlando, FLPinnacle Clinical Research· San Antonio, TXTexas Liver Institute - American Research Corporation· San Antonio, TX

Related Studies